It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The annual ATTD conference wraps up with news about CGMs, including new FDA approvals and a look at CGMs outside of the US, new eyedrops are being studied to treat diabetic eye disease and Beyond Type 1 opens applications for their annual Beyond Scholars.

Transcript and links below

Find out more about Moms’ Night Out 

Please visit our Sponsors & Partners – they help make the show possible!

Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

Omnipod – Simplify Life

Learn about Dexcom 

Edgepark Medical Supplies

Check out VIVI Cap to protect your insulin from extreme temperatures

Learn more about AG1 from Athletic Greens 

Drive research that matters through the T1D Exchange

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

Sign up for our newsletter here

Here’s where to find us:

Facebook (Group)

Facebook (Page)

Instagram

Twitter

Check out Stacey’s books!

Learn more about everything at our home page www.diabetes-connections.com 

Reach out with questions or comments: info@diabetes-connections.com

 

Episode transcription:

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now.

XX

In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark

XX

Our top story this week…

XX

The ATTD Conference wrapped up earlier this week – that’s the Advanced Technology and Treatments Conference that takes place in Europe. It was in Italy this year. Lots of news and studies from there – we’ll touch on a few, but lots of links to additional reports in the show notes. I also have a link to every story I do feature. Let’s dive in!

From where I sit – NOT in Italy, it seems to me that the two big stories from ATTD are CGM options and patient involvement. The latter has come a long way with more patient voices being included on the conference floor and in studies than years ago.

In terms of CGM.. there are more than 30 in development and we got news about some of those.

First, the established players. Dexcom announces that the FDA approved Stelo – their new CGM meant for people with type 2 who don’t use insulin. We’ve covered that a lot – but the surprise here was that it was okayed for Over the Counter distribution. No pricing info yet.. much more to come.

Dexcom also announced FDA approval for G7 direct to watch connection. That means no smartphone needed – the G7 will transmit directly to Apple Watch. Both Stelo and this feature expected by the end of summer.

Stelo OTC

https://www.bmj.com/content/384/bmj.q611

XX

In terms of studies, new data shows long-term use of an AID system powered by Dexcom CGM can safely maintain improvements in glycemic outcomes for up to two years1.

Real-world evidence demonstrates reduction in severe hypoglycaemia and diabetic ketoacidosis over 12 months in people with Type 1 diabetes using a Dexcom-powered Automated Insulin Delivery (AID) system2.

Also.. new study shows an association between Dexcom CGM usage and a meaningful reduction in HbA1c for people treating their T2D with a GLP-1.

https://www.businesswire.com/news/home/20240305323546/en/Dexcom-Showcases-Leadership-in-AID-and-Power-of-Dexcom-CGM-in-Type-2-Diabetes-With-New-Data-at-ATTD

XX

Freestyle Libre releases a similar study, showing that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology. Better HbA1c results were achieved irrespective of GLP-1 duration, GLP-1 type, or insulin therapy type

https://abbott.mediaroom.com/2024-03-06-Real-World-Data-Show-Abbotts-FreeStyle-Libre-R-Systems-and-GLP-1-Medicines-Work-Better-Together-for-People-with-Type-2-Diabetes

XX

Roche debuted its first continuous glucose monitor (CGM) offering that utilizes predictive AI. The company unveiled its Accu-Chek SmartGuide which is an investigational device not yet authorized for sale. Accu-Chek SmartGuide features a 14-day wear time but does require initial calibration.

 

The company reports a mean absolute relative difference (MARD) of 9.2% based on a 48-patient study, according to BTIG analysts. MARD is a measurement of accuracy for CGM, with lower percentages highlighting stronger accuracy. For instance, Dexcom’s G7 previously demonstrated a MARD of 8.2%, while Abbott’s FreeStyle Libre 3 came in at 7.6%.

Roche unveils new CGM tech with predictive AI, outlines diabetes strategy

XX

 

Photo courtesy of i-SENS

The South Korean Ministry of Food and Drug Safety has approved the first locally-developed continuous glucose monitoring device.

The CareSens Air, developed by blood glucose device maker i-SENS, is touted to be the smallest and lightest CGM device available in South Korea. It can also be used for 15 days straight and features a calibration mechanism to make readings more reliable.

CareSens Air is also the fourth CGM device that has been approved by the South Korean government, following approvals for foreign products by Medtronic, Abbott, and Dexcom.

Moreover, i-SENS is currently seeking a CE clearance for its CGM offering, eyeing to market the product in Europe by the first half of 2024.

https://www.mobihealthnews.com/news/asia/south-korea-approves-first-local-cgm-device

XX

As I said, lotta CGM news! Elsewhere..

MannKind Corporation announced initial meal challenge data from INHALE-3 a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.

The statistically significant findings included: Subjects utilizing inhaled insulin experienced significantly reduced post-meal hyperglycemia, compared with those who used subcutaneous rapid-acting analogues (RAA) delivered by MDI or pumps Area under the curve (AUC; 180 mg/dL) was reduced by 20%; Inhaled insulin subjects demonstrated significantly lower glucose excursions from baseline; Mean glucose excursions were reduced by 22%; In the inhaled insulin group, mean glucose levels peaked 15 minutes sooner than in the standard of care group despite inhaled insulin being given at start of the meal vs. RAA being administered 5-15 minutes prior to the meal. The 17-week endpoint results from INHALE-3 will be presented Saturday, June 22, during a symposium at the American Diabetes Association?s 84th Scientific Sessions in Orlando.

https://www.marketscreener.com/quote/stock/MANNKIND-CORPORATION-34185045/news/MannKind-Corporation-Announces-INHALE-3-Study-s-Initial-Meal-Challenge-Results-Comparing-Afrezza-H-46141572/

XX

A new eye drop could mean a much simpler solution for diabetic eye disease. Current treatments for diabetic retinopathy and diabetic macular edema are invasive and include medication injections into the eye and laser therapy. New study on the eye drops reported it safe and tolerable.. 100% of people stayed in the study which is significant.

Researchers also reported a significant decrease in central macular thickness after 85 days of use, as well as inhibition of further increases in vascular leakage in study participants using the eye drop

 

“Finding a noninvasive, safe, and efficacious treatment for non-proliferative diabetic retinopathy patients would help prevent progression to more severe disease at an early stage,” he continued.

The new eye drop, called EXN407, is reportedly the first topical treatment for retinal vascular diseases such as diabetic retinopathy and diabetic macular edema.

https://www.medicalnewstoday.com/articles/could-an-intervention-as-simple-as-eye-drops-treat-eye-damage-in-diabetes

XX

High-dose of vitamin D analog can prolong the remission period of type 1 diabetes (T1D) by preserving the function of insulin-producing beta cells in newly diagnosed patients.

Researchers conducted a secondary post hoc analysis of a randomized clinical trial looking at residual beta function and vitamin D supplementation in 36 youths (age, 10-21 years; mean age, 13.5 years; 33.3% women) with recently diagnosed T1D.

Participants were randomly assigned to receive vitamin D (50,000 international units) or placebo every week for 2 months and then biweekly for 10 months.

Vitamin D supplementation improved the insulin secretion capacity of beta cells, as observed by the decrease in the mean fasting PI:C ratio compared with placebo (−0.0009 vs 0.0011; P =.01).

The reduction in %ΔAUC of C-peptide was notably slower with vitamin D than placebo (−2.8% vs −4.7%; P =.03), indicating a longer delay in the loss of C-peptide.

https://www.medscape.com/viewarticle/vitamin-d-supplement-protects-insulin-producing-cells-t1d-2024a10004mb

XX

In the UK. Oxford University researchers are to establish a national registry to track individuals at risk of developing type 1 diabetes. The measure is targeted at those who test positive for diabetes autoantibodies – proteins that indicate potential pancreatic damage and possible future diagnosis of type 1 diabetes.

The expectation is for enrolment into the registry to star later this year.

The registry aims to share information about upcoming treatments and opportunities for participation in research, such as trials of immunotherapy treatments.

 

https://www.oxfordmail.co.uk/news/24178874.oxford-establishing-diabetes-registry-people-at-risk/

XX

Commercial

XX

March 12, 2024 — The Food and Drug Administration announced last week that it will allow yogurt producers to say that regular consumption of their products may prevent Type 2 diabetes, but labels must also include the qualification that this is based on “limited scientific evidence.”

There has been some research that supports this claim, Frank Hu, Fredrick J. Stare Professor of Nutrition and Epidemiology and chair of the Department of Nutrition at Harvard T.H. Chan School of Public Health, said in a March 5 New York Times article. For example, a 2014 study by Hu and colleagues found an association between regular consumption of yogurt—but not other forms of dairy—and lowered Type 2 diabetes risk. Hu said in the article that the live bacteria cultures in yogurt may reduce inflammation and insulin resistance.

Yogurt is high in protein, vitamins, and minerals, and can be part of a healthy diet if it’s not loaded with added sugars, Hu said. However, yogurt is unlikely to prevent diabetes on its own, according to Hu and other experts quoted in the article.

To lower diabetes risk, Hu suggested consuming a dietary pattern such as the Mediterranean diet, maintaining a healthy weight, and limiting consumption of products linked to increased diabetes risk, including sugary beverages and processed meats. Yogurt, he noted, is “not a magic bullet.”

Read the New York Times article: Does Eating Yogurt Reduce Your Diabetes Risk?

 

Eating yogurt may help reduce Type 2 diabetes risk

XX

 

Beyond Scholars is a scholarship program designed specifically for the diabetes community.

 

Originally founded as the Diabetes Scholars Foundation in 2008, the program officially became a part of the Beyond Type 1 portfolio in 2018. Beyond Scholars offers scholarships of up to $5,000 for students living with diabetes as they pursue their educational dreams.

 

“Pursuing post-secondary education is no small—or inexpensive—feat, especially if you are a student living with a chronic illness,” says Kristian Hurley,  Senior VP of Programs, Advocacy and Health Equity at Beyond Type 1.. “We are incredibly proud to offer resources to this talented and deserving class of grads, and the many alumni before them.”

 

Since 2008 Beyond Scholars has provided students more than $2 million in scholarship money. Scholarships are made possible by individual and corporate donors.

 

To apply for a scholarship, click here.

 

The deadline for submissions is April 19, 2024.

Beyond Scholars

XX

XX

Join us again soon!

Leave a Reply